diffuse intrinsic pontine glioma

  •   George Lundberg, MD

    This clinical case study published in the scientific journal Cureus suggests that intelligent, compassionate, palliative care is likely the best approach to this very difficult brain tumor.

    .

  •   George Lundberg, MD

    As announced by Cancer Commons partner the Musella Foundation For Brain Tumor Research & Information, Inc., a collaboration of groups has announced funding to support research into possible treatments for pediatric diffuse intrinsic pontine glioma (DIPG).

    .

  •   George Lundberg, MD

    A press release from the Children’s Cancer Institute outlines hopeful results from experiments performed in mice and 3-D computer models that investigated a new treatment for the rare childhood brain tumor diffuse intrinsic pontine glioma (DIPG). The treatment consists of a combination of the drugs difluoromethylornithine (DFMO) and AMXT 1501. This combo is already being tested in clinical trials in adults with cancer, and will soon be tested in children with DIPG.

    .

  •   Erika Vial Monteverdi

    Press release from Oncoceutics curated by Executive Director Erika Vial Monteverdi.

    The U.S. Food and Drug Administration has granted Rare Pediatric Disease Designation to the drug ONC201 for treating a type of brain tumor known as “H3 K27M-mutant glioma,” which is primarily found in children. Alongside the Musella Foundation For Brain Tumor Research & Information, Inc, and the company xCures, Cancer Commons has been supporting this program to help patients in need.

    Go to full article published by Novocure on Business Wire.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  •  

    Facilitating Access to Treatment for Children with Brain Cancer

    With: Leslie Jared, RN, MSN

    A Q&A with Leslie Jared, RN, MSN, Nurse Navigator at Cancer Commons. Email: leslie.jared@cancercommons.org Q: A midline glioma is a type of brain tumor that is particularly dangerous because of its nature and its location in the brain. It often afflicts children. An investigational drug called ONC201 has shown early promise in some patients whose tumors have a specific genetic mutation called H3 K27M.… Read more »

  •   George Lundberg, MD

    Article from EurekAlert curated by Editor in Chief George Lundberg, MD, who notes: 

    Researchers have shown that a combination therapy is effective against cancer cells in test-tube experiments and laboratory animals. It has not yet been tested in humans.

    Go to full article published by EurekAlert.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  •   George Lundberg, MD

    Article from ScienceDaily curated by Editor in Chief George Lundberg, MD, who notes: 

    A genetic mutation known as PPN1D has been found to be a possible point of attack for research into the childhood cancer diffuse intrinsic pontine glioma (DIPG).

    Go to full article published by ScienceDaily.

  •   George Lundberg, MD

    Curated by Editor in Chief George Lundberg, MD, who notes:

    DIPG is a rare, malignant brain tumor. Three hundred Americans, usually children, are diagnosed with DIPG each year. Its location (pons), its sublocation (intrinsic), its growth character (diffuse), and its cell type (glioma) describe a very difficult cancer to treat. Here is how one prestigious cancer center (Dana-Farber Cancer Institute) explains DIPG.

    .

  •   George Lundberg, MD

    Curated by Editor in Chief George Lundberg, MD:

    A brainstem glioma is a very serious disease that is rare and mostly affects children. Diffuse pontine intrinsic glioma  (DPIG) is one type of brainstem glioma. For an authoritative, up-to-date, detailed, comprehensive, and unbiased overview of brainstem gliomas, check out this presentation and discussion. (You may be required to register for free to view it.)

     

  •  

    Case Report in the Journal of Neurosurgery Highlights Potential of ONC201 in H3 K27M-mutant DIPG

    Last fall, we announced our collaboration with Musella Foundation, xCures, The Cure Starts Now Foundation, Michael Mosier Defeat DIPG Foundation, and Oncoceutics to help patients access ONC201, a new, experimental treatment for a type of brain tumor known as diffuse intrinsic pontine glioma (DIPG), as well as other gliomas with a genetic mutation known as H3 K27M. Oncoceutics now reports the publication of a case study of a 10-year-old patient for whom ONC201… Read more »